HOME >> MEDICINE >> NEWS
Little evidence behind bronchodilator therapy for cystic fibrosis

group of the cystic fibrosis patients studied. These patients were known to have bronchial hyper-responsiveness -- increased response of the airway to certain stimuli. Bronchial hyper-responsiveness and responsiveness to bronchodilator drugs are markers for asthma and can be also tested for in people with cystic fibrosis.

The reviewers found the following:

  • Albuterol and terbutaline -- drugs classified as short-acting beta2-agonists -- increased FEV1 and peak expiratory flow rate for patients known to have bronchial hyper-responsiveness.

  • Serevent (salmeterol) -- classified as a long-acting beta2-agonist -- also improved lung function for participants known to have bronchial hyper-responsiveness.

  • Atrovent (ipratropium bromide) showed no consistent effects on lung function in the trials under review.

The reviewers found no published trials that included inhaler-delivered fenoterol, formoterol or tiotropium and wrote that use of those agents could not be supported.

The reviewers noted that the trials were too varied in design to allow for a pooling of data for a strict meta-analysis.

"[B]efore embarking on what might become lifelong bronchodilator therapy, bronchodilator responsiveness should be assessed by measuring lung function both before and after a test dose of salbutamol in a standardized way, looking for an increase in baseline FEV1 of at least 10 percent," the reviewers concluded.

John Colombo, M.D., professor and chief of the pediatric pulmonology section at the University of Nebraska Medical Center, said, "My bias is that all CF [cystic fibrosis] patients deserve a trial of beta-agonist bronchodilator. This should be done in the PFT [pulmonary function test] laboratory, and, unless they develop significant adverse effects, short-acting beta-agonists should be considered as a trial for symptom relief, and possibly as an adjunct to airway clearance. A long-acting beta-agon
'"/>

Contact: Clare Halfhide
chalfhide@hotmail.com
Center for the Advancement of Health
25-Oct-2005


Page: 1 2 3

Related medicine news :

1. Little difference between human insulin and faster-acting drugs
2. Little change in suicidal thoughts, plans or attempts in US
3. Little evidence found for IVF as most effective infertility treatment
4. Little answers to worlds biggest problems
5. Majority of herb users dont follow evidence-based indications, researchers find
6. No evidence older women generate new eggs
7. Opportunistic chlamydia screening not underpinned by sound evidence
8. Drug safety recommendations lack scientific evidence
9. Study links attempted suicide with genetic evidence identified in previous suicide research
10. Fosrenol data show evidence of trends towards improved bone formation in CKD stage 5 patients
11. Mayo Clinic researchers find evidence for traumatic cause of carpal tunnel syndrome

Post Your Comments:
(Date:6/19/2013)... 19, 2013 Brightree LLC , ... software solutions for the post-acute care industry, has been ranked ... the Healthcare Informatics 100 (HCI 100) list. This ... the U.S. in terms of revenue during the last fiscal ... rate of 85% annually, and the company has built its ...
(Date:6/19/2013)... Boca Raton, FL (PRWEB) June 19, 2013 ... spoke about the positive changes and growth that has occurred ... his nationwide travel club. , Shuman said, "Travel Services has ... program to heights beyond belief. Membership is up, even ... agents to meet the demands of members." , Having been ...
(Date:6/19/2013)... disease Amyotrophic lateral sclerosis (ALS), also known as Lou ... can be classified into four distinct stages, report pathologists ... of Pennsylvania in the Annals of Neurology . ... tissues shows, for the first time, how the fatal ... the central nervous system to other regions of brain ...
(Date:6/19/2013)... derived from a naturally occurring compound (apocynin), has ... with Parkinson,s Disease symptoms by preventing deficits in ... the May 28, 2013 edition of ... postdoctoral fellow at the Medical College of Wisconsin ... Balaraman Kalyanaraman, Ph.D., Harry R. & Angeline ...
(Date:6/19/2013)... Imprivata ®, a leading global provider ... Imprivata OneSign ® leads the single sign-on (SSO) category ... & Services report . CIOs and other healthcare executives ... performance of its products and the quality of its ... is integral to their long-term healthcare IT strategy. ...
Breaking Medicine News(10 mins):Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 2Health News:Brightree Debuts on List of Top 100 Healthcare Technology Companies 3Health News:Former Owner Eric Shuman Endorses New Owners and Changes Made in Last Year Since Shuman Sold Travel Services Center at Member Conference 2Health News:Staging system in ALS shows potential tracks of disease progression, Penn study finds 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 2Health News:Imprivata Tops Single Sign-On Category in KLAS 2013 Mid-Term Performance Review 3
(Date:6/19/2013)... , June 19, 2013   Life Technologies ... a licensing agreement granting Suzhou Ribo Life Sciences ... siRNA therapeutics in China ... formulate proprietary siRNA molecules in combination with Invivofectamine® ... address human diseases with high unmet medical need ...
(Date:6/19/2013)... , 19. Juni 2013 ... mit der Entwicklung von SCS microRESIST™, ... in der Beschichtung mit Parylene gelungen ... von biokompatiblem Parylene mit antimikrobiellen Eigenschaften ... schädlicher Mikroorganismen auf beschichteten medizinischen Geräten. ...
(Date:6/18/2013)... , June 18, 2013  Intercept Pharmaceuticals, Inc.  ... company focused on the development and commercialization of novel ... announced the pricing of an underwritten public offering of ... offering price of $33.01 per share.  In addition, Intercept ... up to an additional 259,500 shares of common stock. ...
Breaking Medicine Technology:Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 2Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 3Life Technologies Signs Licensing Agreement with Suzhou Ribo Life Sciences for Development of siRNA Therapeutics in China 4Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock 2
Cached News: